174 related articles for article (PubMed ID: 32995478)
1. Biodistribution Analysis of Oncolytic Adenoviruses in Canine Patient Necropsy Samples Treated with Cellular Virotherapy.
Gómez A; Sardón D; Cejalvo T; Vázquez F; García-Castro J; Perisé-Barrios AJ
Mol Ther Oncolytics; 2020 Sep; 18():525-534. PubMed ID: 32995478
[TBL] [Abstract][Full Text] [Related]
2. Systemic cellular viroimmunotherapy for canine high-grade gliomas.
Cloquell A; Mateo I; Gambera S; Pumarola M; Alemany R; García-Castro J; Perisé-Barrios AJ
J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600663
[TBL] [Abstract][Full Text] [Related]
3. AKT and JUN are differentially activated in mesenchymal stem cells after infection with human and canine oncolytic adenoviruses.
Rodríguez-Milla MÁ; Morales-Molina A; Perisé-Barrios AJ; Cejalvo T; García-Castro J
Cancer Gene Ther; 2021 Feb; 28(1-2):64-73. PubMed ID: 32457488
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model.
Rincón E; Cejalvo T; Kanojia D; Alfranca A; Rodríguez-Milla MÁ; Gil Hoyos RA; Han Y; Zhang L; Alemany R; Lesniak MS; García-Castro J
Oncotarget; 2017 Jul; 8(28):45415-45431. PubMed ID: 28525366
[TBL] [Abstract][Full Text] [Related]
5. Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: an exploratory study.
García-Castro J; Alemany R; Cascalló M; Martínez-Quintanilla J; Arriero Mdel M; Lassaletta A; Madero L; Ramírez M
Cancer Gene Ther; 2010 Jul; 17(7):476-83. PubMed ID: 20168350
[TBL] [Abstract][Full Text] [Related]
6. Human mesenchymal stem cells lack tumor tropism but enhance the antitumor activity of oncolytic adenoviruses in orthotopic lung and breast tumors.
Hakkarainen T; Särkioja M; Lehenkari P; Miettinen S; Ylikomi T; Suuronen R; Desmond RA; Kanerva A; Hemminki A
Hum Gene Ther; 2007 Jul; 18(7):627-41. PubMed ID: 17604566
[TBL] [Abstract][Full Text] [Related]
7. Remission of Spontaneous Canine Tumors after Systemic Cellular Viroimmunotherapy.
Cejalvo T; Perisé-Barrios AJ; Del Portillo I; Laborda E; Rodriguez-Milla MA; Cubillo I; Vázquez F; Sardón D; Ramirez M; Alemany R; Del Castillo N; García-Castro J
Cancer Res; 2018 Sep; 78(17):4891-4901. PubMed ID: 29991502
[TBL] [Abstract][Full Text] [Related]
8. Tumor-Homing of Mesenchymal Stem Cells Infected with Oncolytic Virus in a Canine Patient.
Delgado-Bonet P; Tomeo-Martín BD; Ortiz-Díez G; Perisé-Barrios AJ
Vet Sci; 2022 Jun; 9(6):. PubMed ID: 35737337
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of biodistribution of a fiber-chimeric, conditionally replication-competent (oncolytic) adenovirus in CD46 receptor transgenic mice.
Ganesh S; Gonzalez-Edick M; Gibbons D; Waugh J; Van Roey M; Jooss K
Hum Gene Ther; 2009 Oct; 20(10):1201-13. PubMed ID: 19572803
[TBL] [Abstract][Full Text] [Related]
10. Adenovirus and Immunotherapy: Advancing Cancer Treatment by Combination.
Sato-Dahlman M; LaRocca CJ; Yanagiba C; Yamamoto M
Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32455560
[TBL] [Abstract][Full Text] [Related]
11. First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors.
Ruano D; López-Martín JA; Moreno L; Lassaletta Á; Bautista F; Andión M; Hernández C; González-Murillo Á; Melen G; Alemany R; Madero L; García-Castro J; Ramírez M
Mol Ther; 2020 Apr; 28(4):1033-1042. PubMed ID: 32053771
[TBL] [Abstract][Full Text] [Related]
12. Giving Oncolytic Viruses a Free Ride: Carrier Cells for Oncolytic Virotherapy.
Reale A; Calistri A; Altomonte J
Pharmaceutics; 2021 Dec; 13(12):. PubMed ID: 34959474
[TBL] [Abstract][Full Text] [Related]
13. Studies on the Interaction of Tumor-Derived HD5 Alpha Defensins with Adenoviruses and Implications for Oncolytic Adenovirus Therapy.
Vragniau C; Hübner JM; Beidler P; Gil S; Saydaminova K; Lu ZZ; Yumul R; Wang H; Richter M; Sova P; Drescher C; Fender P; Lieber A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077642
[TBL] [Abstract][Full Text] [Related]
14. Cellular Virotherapy Increases Tumor-Infiltrating Lymphocytes (TIL) and Decreases their PD-1
Morales-Molina A; Rodríguez-Milla MÁ; Gimenez-Sanchez A; Perisé-Barrios AJ; García-Castro J
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708639
[TBL] [Abstract][Full Text] [Related]
15. Fighting Cancer with Viruses: Oncolytic Virus Therapy in China.
Wei D; Xu J; Liu XY; Chen ZN; Bian H
Hum Gene Ther; 2018 Feb; 29(2):151-159. PubMed ID: 29284308
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution Analysis of Oncolytic Adenoviruses in Patient Autopsy Samples Reveals Vascular Transduction of Noninjected Tumors and Tissues.
Koski A; Bramante S; Kipar A; Oksanen M; Juhila J; Vassilev L; Joensuu T; Kanerva A; Hemminki A
Mol Ther; 2015 Oct; 23(10):1641-52. PubMed ID: 26156245
[TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cell carriers enhance anti-tumor efficacy of oncolytic virotherapy.
Wang X; Zhao X; He Z
Oncol Lett; 2021 Apr; 21(4):238. PubMed ID: 33664802
[TBL] [Abstract][Full Text] [Related]
18. Modulation of viability and maturation of human monocyte-derived dendritic cells by oncolytic adenoviruses.
Schierer S; Hesse A; Müller I; Kämpgen E; Curiel DT; Schuler G; Steinkasserer A; Nettelbeck DM
Int J Cancer; 2008 Jan; 122(1):219-29. PubMed ID: 17764070
[TBL] [Abstract][Full Text] [Related]
19. Targeting the tumor stroma with an oncolytic adenovirus secreting a fibroblast activation protein-targeted bispecific T-cell engager.
de Sostoa J; Fajardo CA; Moreno R; Ramos MD; Farrera-Sal M; Alemany R
J Immunother Cancer; 2019 Jan; 7(1):19. PubMed ID: 30683154
[TBL] [Abstract][Full Text] [Related]
20. Systemic oncolytic adenovirus delivered in mesenchymal carrier cells modulate tumor infiltrating immune cells and tumor microenvironment in mice with neuroblastoma.
Franco-Luzón L; González-Murillo Á; Alcántara-Sánchez C; García-García L; Tabasi M; Huertas AL; Chesler L; Ramírez M
Oncotarget; 2020 Jan; 11(4):347-361. PubMed ID: 32064039
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
